

B3
CK

additions and/or insertions such that the ability of the variant to react with antigen-specific T cell lines or clones is not substantially diminished; and

(b) a non-specific immune response enhancer that preferentially enhances a T cell response in a patient;

wherein said WT1 polypeptide comprises the contiguous amino acids of SEQ ID NO:2 or 3.

111. A immunogenic composition according to claim 110, wherein the immune response enhancer is selected from the group consisting of Montanide ISA50, Seppic Montanide ISA 720, a cytokine, a microsphere, dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants, AS-1, AS-2, Ribi Adjuvant system based adjuvant, QS21, saponin based adjuvants, Syntex adjuvant in its microfluidized form, MV, ddMV, immune stimulating complex (iscom) based adjuvants, and inactivated toxins.

112. The immunogenic composition of claim 111, wherein said cytokine is selected from the group consisting of GM-CSF and Flat3-ligand.--

REMARKS

Applicants submit this response to the Restriction Requirement dated October 4, 2000. In response, Applicants have elected Group I, claims 1-9, 11, 12, 13, and 14-22. The Examiner also required election of a specific SEQ ID NO. Applicants traverse this requirement on the grounds that all the claimed peptides are portions of one protein, WT1, and a search for WT1 would necessarily include the claimed peptides. Thus, it would not be an undue burden on the Examiner to examine all the claimed peptides.


However, in an effort to advance the prosecution, Applicants have selected the peptide having the amino acid sequence of SEQ ID NO:2 (which is identical to SEQ ID NO:3). Applicants have cancelled claims 1-9, 11, 12, 13, and 14-22, which have been rewritten as claims 104-112. These claims are supported by original claims 1-9, 11, 12, 13, and 14-22, and by the

specification at, for example, page 44, Table I, line 3 (p117-139, SEQ ID NO:2 and 3); and page 97, lines 7-17.

Consideration of the elected claims is now requested.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jane E. R. Potter
Registration No. 33,332

JEP:sds

Enclosure:

Postcard

Check

Petition for an Extension of Time (+2 copies)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031
U:\sharons\210121\465